comparemela.com

Latest Breaking News On - Steve worland - Page 3 : comparemela.com

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expect.

United-states
Kevin-gardner
Christian-curtis
Jennifer-caswell-jin
Mike-tattory
Christopherm-calabrese
Steve-worland
University-of-california-san-francisco
Northwestern-university
Nasdaq
Effector-therapeutics-inc
Lifesci-communications

The surprising clause in Home and Away star Georgie Parker's TV contract revealed as she prepares for new project

Gold Logie winner Georgie Parker has opened up about the surprise clause in her Home and Away contract.

Sydney
New-south-wales
Australia
Kirribilli
Alf-stewart
Ray-meagher
Kate-raison
David-williamson
Steve-worland
Georgie-parker
Gold-logie

EFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024

-  Summary of development progress for tomivosertib and zotatifin and a preview of anticipated 2024 milestones- -  Review of recently announced interim data from dose escalation and Phase 2.

United-states
Christopherm-calabrese
Steve-worland
Kevin-kalinsky
Mike-tattory
Kevin-gardner
Oncology-at-emory-university-school-of-medicine
Pfizer
Effector-therapeutics-inc
Exchange-commission
Winship-cancer-institute
Nasdaq

eFFECTOR Therapeutics to Host Virtual Investor R&D Day on

-  Summary of development progress for tomivosertib and zotatifin and a preview of anticipated 2024 milestones- -  Review of recently announced interim.

United-states
Steve-worland
Mike-tattory
Kevin-gardner
Christopherm-calabrese
Kevin-kalinsky
Lifesci-communications
Effector-therapeutics-inc
Department-of-hematology
Winship-cancer-institute
Glenn-family-breast-center
Pfizer

eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024 - eFFECTOR Therapeutics (NASDAQ:EFTR)

- Summary of development progress for tomivosertib and zotatifin and a preview of anticipated 2024 milestones- - Review of recently announced interim data from dose escalation and Phase 2 expansion cohorts of

United-states
Steve-worland
Kevin-kalinsky
Winship-cancer-institute
Oncology-at-emory-university-school-of-medicine
Department-of-hematology
Glenn-family-breast-center
Pfizer
Exchange-commission
Effector-therapeutics-inc
Medical-oncology
Emory-university-school

vimarsana © 2020. All Rights Reserved.